Ivim Health
GLP-1 telehealth platform with peer-reviewed clinical outcomes data, offering compounded semaglutide and tirzepatide alongside women's hormone therapy across 49 states.
What we like
What to watch
Full Review
Ivim has built a meaningful position in the telehealth GLP-1 market with 600,000+ registered patients and peer-reviewed clinical data demonstrating above-benchmark weight loss outcomes (21.8% average body weight loss at 68 weeks). The bootstrapped company has scaled without external funding, though its business model carries concentrated risk: revenue depends heavily on compounded semaglutide and tirzepatide, both of which face ongoing FDA and legal challenges. The February 2026 FDA warning letter regarding misleading product labeling adds a trust concern. While the volume of positive Trustpilot reviews and app ratings suggests genuine patient satisfaction, aggressive refund policies and rising BBB complaint volume indicate operational growing pains.
Last researched: 2026-03-30
Pricing
| Treatment | Category | Price/mo | Includes | Notes |
|---|---|---|---|---|
| Compounded Semaglutide (12-month plan) | Weight Loss / GLP-1 | $150–$175 | ● Consults○ Lab work● Shipping | First month membership free Subscription required |
| Compounded Semaglutide (6-month plan) | Weight Loss / GLP-1 | $175 | ● Consults○ Lab work● Shipping | First month membership free Subscription required |
| Compounded Tirzepatide (12-month plan) | Weight Loss / GLP-1 | $208 | ● Consults○ Lab work● Shipping | First month membership free Subscription required |
| Women's Hormone Optimization | Weight Loss / GLP-1 | $199 | ● Consults○ Lab work● Shipping | Subscription required |